Intensive Care Patients after Surgery treated with Daptomycin and wound draingae
Conditions
Interventions
Trade Name: Cubicin
Product Name: Cubicin
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: DAPTOMYCIN
CAS Number: 103060-53-3
Concentration unit: mg milligram(s)
Concentratio
Sponsors
University Hospital Tübingen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: * Patients = 18 /=65 years) yes F.1.3.1 Number of subjects for this age range 2
Exclusion criteria
Exclusion criteria: Schwangerschaft (Ausschluss per routinemäßigem Schwangerschaftstest bei weiblichen Notfallpatientinnen 85 years * documented allergy to daptomycin * acute rhabdomyolysis (increase in Kreatinphosphokinase and Laktatdehydrogenase > fivefold of upper limit: Kreatinphosphokinase >950U/l, Laktatdehydrogenase >1250 U/l) * patients dependent on sponsor, manufactor or principle investigator or their relatives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Pharmakokinetics of Daptomycin in intensive care patients with wound drainage after surgery;Secondary Objective: Incidence of gram-positive infection; LOS ICU LOS Hospital;Primary end point(s): Pharmakokinetic of daptomycin in blood; elimination of daptomycin n drainage;Timepoint(s) of evaluation of this end point: Postoperative day 1-3 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): LOS ICU and hospital;Timepoint(s) of evaluation of this end point: Release of ICU and relase of hospital | — |
Countries
Germany
Contacts
Public ContactIntensive Care Unit 39
University Hospital Tübingen
Outcome results
None listed